NAT2 and tuberculosis: Further, we aimed to compare and characterize the NAT2 pharmacogenomic diversity from our studied population with several populations of different countries through a literature review of the studies reporting on the NAT2 SNP frequency in different TB and AT-DILI populations as well as from the participants of the ‘All of Us’ Research Program database from the Public Tier dataset.